Methylenum (Coeruleum, Methylene Blue) Veterinary Grade API is released as methylthioninium chloride hydrate, C₁₆H₁₈ClN₃S·xH₂O, with a relative molecular mass of 319.85 g/mol on the anhydrous basis and 373.90 g/mol for the trihydrate, Colour Index 52015. The veterinary grade is intended for formulation into tablets, injections, capsules, powders, granules, premixes, and solutions under a monograph-aligned release specification. Two physical-grade designations are available: a micronized grade with D90 ≤ 30 µm by laser diffraction according to ISO 13320:2020, and a standard powder grade with D90 ≤ 150 µm. The micronized material is assigned to low-dose dry blends and premixes where colour dispersion serves as a visible verification of homogeneity; the standard powder is used for solution preparation and wet granulation. Packaging is heat-sealed aluminium laminate with desiccant because the hydrate exchanges water with ambient moisture and can cause assay drift during open handling.

What are the compendial release criteria and physicochemical identifiers?

Methylenum Veterinary Grade API is controlled against Ph. Eur. 0026 for methylthioninium chloride hydrate. The identification battery includes UV/Vis absorption at λmax 664 nm in aqueous solution, infrared concordance with a reference standard, and chloride precipitation after oxygen-flask combustion. Assay by perchloric acid titration of the dried material is 98.5–101.0%; the acceptance range for water content by loss on drying is 8.0–16.0% for the hydrate grade, using the method Ph. Eur. 2.2.32. Sulfated ash is controlled at ≤ 0.1% by Ph. Eur. 2.4.14, and heavy metals by method Ph. Eur. 2.4.8 are limited to ≤ 20 ppm as lead. Related substances by liquid chromatography are limited to total ≤ 1.0%, with individual azure homologues and demethylated impurities controlled because their presence shifts the visible spectrum and changes staining or redox behaviour. Residual solvents are controlled under VICH GL18; Class 1 solvents are absent at reporting threshold, and Class 2 solvents are within animal-safety limits. For parenteral applications, bacterial endotoxin testing by Ph. Eur. 2.6.14 is applied at a limit agreed with the manufacturing authorization holder, typically ≤ 2.5 EU/mg for low-volume injection processes; if no endotoxin limit is agreed, the material is released as a non-sterile API with bioburden control per Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13.

For injectable solutions, methylene blue is dissolved in water for injection at a concentration commonly between 0.1% w/v and 5.0% w/v; the solution is sparged with nitrogen because the phenothiazinium chromophore undergoes photoreduction and oxidative demethylation to Azure B and Azure A when oxygen and visible light are present. Terminal sterilisation at 121 °C for 15 min is usually acceptable only when the pH is maintained between 3.0 and 5.5 and the headspace oxygen content is below 2%. Above pH 9, the hydrochloride is converted to the poorly water-soluble free base, producing visible precipitation and uneven dose delivery through 0.45 µm membranes. Reducing agents such as ascorbic acid or sodium metabisulfite reduce the dye to leuco-methylene blue, causing reversible colour loss and loss of the active redox capacity used in methemoglobinemia management. Glass Type I vials with ultraviolet-protective labelling or cartons are used because light transmission below 500 nm accelerates photodegradation in clear borosilicate vials; published data for this specific configuration is limited, and development batches should be assessed under VICH GL3 photostability conditions. Filtration through polyethersulfone or PVDF membranes with 0.22 µm porosity is performed before aseptic filling; nylon membranes can adsorb the dye and must be assessed with product solution before use.

Tablet, Capsule, and Oral Powder Dosage-Form Constraints

Direct compression of methylene blue at doses below 1 mg per tablet is difficult because the neat API has poor flow and a bulk density of approximately 0.45–0.75 g/mL measured by USP <616>, depending on micronization and hydrate state. A pre-blend is prepared by geometric dilution with microcrystalline cellulose and croscarmellose sodium in a bin blender operated at 10–15 rpm for 20–30 min; the addition of 0.5–1.0% w/w colloidal silicon dioxide improves flow and reduces segregation. In high-shear granulation, aqueous binder causes dye migration to the granule surface during tray drying; the resulting granule colour is not a reliable indicator of active content because surface enrichment can differ from core concentration. A hydroalcoholic binder with ethanol 30–50% v/v reduces migration but requires explosion-proof drying equipment. Blend uniformity is tested according to USP <905>; a routine acceptance limit of 90.0–110.0% label claim with relative standard deviation ≤ 5.0% is used for tablets and capsules. Tablet press speeds above 60,000 tablets/hour increase dusting, and the highly visible blue dust is an early indicator of insufficient containment. Capsule filling on tamping-pin machines requires pin and dosing disc surfaces made of 316L stainless steel; powder adhesion to non-electropolished surfaces causes fill-weight drift across batches.

Medicated feed premixes are manufactured by stepwise geometric dilution because the active is used at final concentrations of 50–200 g/tonne in some veterinary feed formulations, and the colour intensity at these levels is too low for reliable visual confirmation. A typical first dilution of 1 part micronized methylene blue with 9 parts spray-dried lactose or wheat middlings is prepared in a 100 L ribbon blender with an intensifier bar; subsequent dilutions follow the same ratio until the target concentration is reached. Blend uniformity is assessed by HPLC with visible detection at 660 nm, with a limit of quantification of 0.005% w/w of active in the premix. The coefficient of variation across ten sampling points should not exceed 5.0% under feed-safety guidelines. Granules are produced by wet granulation with starch paste and dried in a fluid-bed dryer at inlet air temperature 50–60 °C; product temperature above 70 °C can shift hydrate water and alter assay results if the dried basis is not correctly calculated. Final granules are sieved through 1.0 mm and 0.2 mm screens to remove overs and fines; fines below 0.2 mm are the major source of cross-contamination because they become airborne and deposit on equipment, walls, and seals.

When aqueous vehicles are used for oral and injectable liquids, which pH and redox conditions preserve solubility and redox activity?

Methylene blue is freely soluble in water at acidic and neutral pH, but the free base precipitates above pH 9. Oral solutions and injectable liquids are therefore buffered with citrate or phosphate systems at pH 3.0–5.5. At pH 7.4 and above, the protonated phenothiazinium nitrogen can deprotonate, reducing aqueous solubility and shifting the visible absorption maximum; the colour changes from deep blue to greenish blue, which is not a valid stability indicator. Redox-active excipients are restricted: ascorbic acid, sulfites, and glucose in alkaline solutions reduce the dye to the colourless leuco form, and oxygen reoxidation is slow in sealed containers without headspace oxygen. If a stable blue colour is critical for product identity, formulations must be protected by nitrogen overlay and protected from light above 10,000 lux cumulative exposure. Polyvinyl chloride administration sets and silicone tubing can adsorb methylene blue; low-dose infusion studies should use polyethylene or polypropylene tubing and light-protected lines, following USP <788> for particulate matter and USP <790> for visible light exposure during parenteral administration. Autoclaving is avoided for glucose-containing solutions because Maillard reaction products may consume the dye; sterile filtration is preferred for heat-sensitive compositions.

Because methylene blue is a visible stain, cleaning validation uses swab sampling followed by visual inspection under 1000 lux illumination and HPLC quantification at 660 nm. The acceptance limit for carryover is commonly set at 10 ppm of the previous active in the next product or the toxicologically qualified PDE divided by the maximum daily dose of the next product, whichever is lower. Stainless steel 316L surfaces may retain colour after routine wash cycles unless an acidic detergent followed by a chlorinated alkali cycle is used; alkaline detergents above pH 9 convert the hydrochloride to the free base and reduce cleanability. Polycarbonate and PVC equipment are not recommended for long-term contact because the dye penetrates the polymer matrix and creates residual colour that cannot be removed by standard cleaning-in-place procedures. Dedicated scoops, sieves, and containment isolators are therefore common on oral solid dosage lines processing methylene blue; published data for this specific configuration is limited, and site-specific recovery factors must be generated.

Industrial dye, histology-grade, and human GMP lots are not equivalent to the veterinary API monograph.

The veterinary grade differs from industrial methylene blue in four controlled areas: impurity profile, metal residues, residual solvents, and microbiological quality. Industrial dye lots are manufactured for textile or paper dyeing and are not tested to Ph. Eur. 0026; they may contain copper, zinc, iron, and aromatic amines that are acceptable in non-pharmaceutical processes but not in injectable or feed-grade APIs. Histology-grade methylene blue may be chemically close but is released without endotoxin, bioburden, and residual solvent documentation. Human GMP material may have the same assay and related-substance profile, but its documentation package is aligned with ICH Q7 and ICH Q3C, whereas the veterinary grade is aligned with VICH GL18 for residual solvents and VICH GL10 for impurities. In veterinary feed applications, the API must be assessed for carryover into edible tissues; industrial dye lots have not been evaluated under the same residue depletion criteria. The veterinary grade is supplied with a certificate of analysis, declaration of veterinary use, and, where required, a veterinary DMF or national registration file. Different product types should not be substituted without a documented supplier qualification and change control because impurity and particle-size shifts can alter mixing uniformity, dissolution, and parenteral particulate burden.

Micronization by opposed-jet milling is used to generate the D90 ≤ 30 µm grade, with nitrogen as the carrier gas to reduce dust explosion potential and oxidative surface changes in the phenothiazine ring. The micronized powder is cohesive and poorly flowing; its Carr index can exceed 35% unless a flow aid is added, measured by USP <1174>. The material is incompatible with iron oxide pigments and zinc stearate at high shear because metal ions catalyse demethylation and colour shifts. Preblending with lactose or dicalcium phosphate dihydrate reduces electrostatic charging; relative humidity above 65% increases agglomeration on silo walls. Jet milling increases surface area and accelerates hydrate dehydration, so milled product is immediately packaged in double polyethylene liners inside aluminium laminate. Particle-size distribution is controlled with D10, D50, and D90 values generated by ISO 13320:2020; laser obscuration is maintained at 5–15% to avoid multiple scattering artefacts. If a tablet or capsule process does not require micronization, the standard powder grade is preferred because it has lower dust, lower surface energy, and fewer electrostatic handling losses.